We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Hemofiltration for Contrast-Induced Nephropathy

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified September 2005 by Nara Medical University.
Recruitment status was:  Recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT00158080
First Posted: September 12, 2005
Last Update Posted: December 9, 2005
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Nara Medical University
September 7, 2005
September 12, 2005
December 9, 2005
Not Provided
Not Provided
Prevention of contrast-induced acute renal failure, Elevation of serum creatinine
Same as current
No Changes Posted
Need for hemodialysis
Same as current
Not Provided
Not Provided
 
Hemofiltration for Contrast-Induced Nephropathy
Prevention of Contrast-Induced Nephropathy by Real-Time Hemofiltration
Contrast-induced acute renal failure can be prevented with hemofiltration which is performed during cardiac catheterization
Not Provided
Interventional
Not Provided
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
  • Chronic Kidney Disease
  • Cardiac Catheterization
Procedure: hemofiltration
Not Provided
Kashyap AS, Anand KP, Kashyap S. Hemofiltration and the prevention of radiocontrast-agent-induced nephropathy. N Engl J Med. 2004 Feb 19;350(8):836-8; author reply 836-8.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Unknown status
100
Not Provided
Not Provided

Inclusion Criteria:

  • Patients with serum creatinine>2.0mg/dl and/or GFR<50ml/min

Exclusion Criteria:

  • Emergent cardiac catheterization
  • Patients on chronic dialysis
  • Patients with HYHA>III heart failure
Sexes Eligible for Study: All
20 Years to 90 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Japan
 
 
NCT00158080
K0001
Not Provided
Not Provided
Not Provided
Not Provided
Nara Medical University
Not Provided
Study Director: Yoshihiko Saito, MD, PhD Nara Medical University
Nara Medical University
September 2005

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP